Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults
NCT06151288
Completed
The objective of the study is to evaluate the safety, tolerability and immunogenicity of a single injection of VAX-31 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 50 to 64 years of age in Stage 1. Stage 2 will evaluate the safety, tolerability, and immunogenicity of a single injection of VAX-31 at 3 dose levels compared to PCV20 in adults aged 50 years and older.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
09/16/2024
Locations: AMR Mobile, Mobile, Alabama +24 locations
Conditions: Pneumococcal Vaccines
Register for Updates
Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)
NCT05158140
Completed
The purpose of this study is to evaluate the concomitant and non-concomitant use of messenger ribonucleic acid (mRNA) mRNA-1273, the nucleoside-modified mRNA vaccine for active immunization to prevent coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2), with a 23-valent pneumococcal polysaccharide vaccine (V110) for the prevention of pneumococcal disease, or a 15-valent pneumococcal conjugate vaccine (V114) indicated for the prevention of invasive... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
09/11/2024
Locations: Carbon Health ( Site 0045), North Hollywood, California +45 locations
Conditions: Pneumococcal Infection
Register for Updates
Post COVID-19 Vaccination Analysis in Healthcare Worker Recipients
NCT04922944
Completed
This research study is studying how healthcare worker recipients react after receiving vaccinations for COVID-19. The objective of the study is to evaluate the immune response to COVID-19 vaccination. The immunity will be evaluated over time by measuring serum semi-quantitative SARS-Co-V2 IgG from blood specimens and analyzing vaccine reaction data. SARS-CoV-2 is the name for the virus responsible for COVID-19 infections. IgG, immunoglobulin G, is an antibody found in the blood that protects aga... Read More
Gender:
ALL
Ages:
All
Trial Updated:
09/11/2024
Locations: Huntington Hospital, Pasadena, California
Conditions: Covid19, Vaccine Reaction
Register for Updates
BCG Vaccine for Health Care Workers as Defense Against COVID 19
NCT04348370
Completed
SARS-CoV-2 spreads rapidly throughout the world. A large epidemic would seriously challenge the available hospital capacity, and this would be augmented by infection of healthcare workers (HCW). Strategies to prevent infection and disease severity of HCW are, therefore, desperately needed to safeguard continuous patient care. Bacille Calmette-Guérin (BCG) is a vaccine against tuberculosis, with protective non-specific effects against other respiratory tract infections in in vitro and in vivo stu... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
09/11/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California +5 locations
Conditions: Coronavirus, Coronavirus Infection, Coronavirus as the Cause of Diseases Classified Elsewhere
Register for Updates
A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.
NCT05873751
Completed
Brief Summary: The main purpose of the study is to learn about how well Trumenba vaccine shot works against gonorrhea infection. This study looks at data records from a database in the United States. This study includes patient's data from the database who: * Are 15-30 years old. * Have received at least one dose of Trumenba and a MenACWY vaccine or who have received only MenACWY vaccine. This data has already been collected in the past and is being studied between April and June of 2023.
Gender:
ALL
Ages:
Between 15 years and 30 years
Trial Updated:
09/09/2024
Locations: Pfizer, New York, New York
Conditions: Gonorrhea, Chlamydia, Meningococcal Vaccines
Register for Updates
A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above
NCT05559476
Completed
The purpose of this study is to assess the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when co-administered with the high dose quadrivalent influenza (FLU HD) vaccine in adults aged 65 years and above compared to separate administration of the vaccines.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
09/09/2024
Locations: GSK Investigational Site, Birmingham, Alabama +45 locations
Conditions: Respiratory Syncytial Virus Infections
Register for Updates
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
NCT02432378
Recruiting
This study will evaluate the immunologic and potential clinical effectiveness of intensive locoregional sequential intraperitoneal (IP) cisplatin (IPC) with intravenous (iv) paclitaxel followed by peritoneal infusion of a chemokine modulatory (CKM) regimen composed of a cocktail of IP rintatolimod and interferon-alpha (IFNα) for patients with advanced stage ovarian cancer (III-IV) at primary neoadjuvant setting. In the safety phase I phase, we determined the tolerable dose of IPC-CKM. In this p... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/06/2024
Locations: UPMC CancerCenter at Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania +1 locations
Conditions: Cancer of Ovary, Cancer of the Ovary, Neoplasms, Ovarian, Ovarian Cancer, Ovary Cancer, Ovary Neoplasms
Register for Updates
Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer
NCT02648282
Completed
This study will be looking at whether combining cyclophosphamide, pembrolizumab (an antibody that blocks negative signals to T cells), GVAX (pancreatic cancer vaccine), and SBRT (focused radiation) is effective (anti-tumor activity) and safe in patients with locally advanced pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/30/2024
Locations: The Sidney Kimmel Comprehensive Cancer at Johns Hopkins, Baltimore, Maryland
Conditions: Pancreatic Cancer
Register for Updates
Prospective Trial of Vaccine Responses in Childhood Cancer Survivors
NCT00505063
Active Not Recruiting
This study will look at your body's response to the new immunizations. We want to see how well they will protect you. Immunization is the same as vaccination. Our goal is to protect you as much as we can. We do not want you to have the measles, mumps, or whooping cough. We are doing the study because there is no standard way to re-immunize people after cancer treatments.
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
08/30/2024
Locations: Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, New York
Conditions: Childhood Cancer, Multiple Diseases
Register for Updates
Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years.
NCT04583618
Completed
Primary Objectives: * Assessed the immune response of the 3 SP0202 formulations, Prevnar 13 and Pneumovax 23 30 days after the administration of the single dose vaccination * Assessed the safety profile of the 3 SP0202 formulations, Prevnar 13 and Pneumovax 23
Gender:
ALL
Ages:
Between 50 years and 84 years
Trial Updated:
08/29/2024
Locations: Emmaus Research Center, Inc Site Number : 8400014, Anaheim, California +16 locations
Conditions: Pneumococcal Immunization
Register for Updates
Determining the Relationship Between Gut Microbiota and Immune Response to Influenza or COVID-19 Vaccine
NCT05584735
Recruiting
This study will evaluate the effect of the microorganisms in the gut on how well the flu or COVID-19 vaccine works in people who have a weakened immune system due to inflammatory bowel disease. Participants can expect to be in the study for up to 65 days.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
08/27/2024
Locations: University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
Conditions: Inflammatory Bowel Diseases
Register for Updates
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above
NCT06374394
Active Not Recruiting
This study will assess the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when it is co-administered with a COVID-19 messenger ribonucleic acid (mRNA) vaccine (Omicron XBB.1.5), compared to administration of the vaccines separately in adults aged 50 years and above.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
08/27/2024
Locations: GSK Investigational Site, Coral Gables, Florida +23 locations
Conditions: Respiratory Syncytial Virus Infections
Register for Updates